Anika Therapeutics, Inc. (ANIK) Reports Q3 EPS of 22c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $21.11 +1.15%
Revenue Growth %: +5.5%
Financial Fact:
Research & development: 2.82M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Revenue Growth %: +5.5%
Financial Fact:
Research & development: 2.82M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q3 EPS of $0.22, vs. the analyst estimate of $0.11. Revenue for the quarter came in at $18.5 million versus the consensus estimate of $15.1 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
- Yext, Inc. (YEXT) Tops Q2 EPS by 4c
- Elastic N.V. (ESTC) Tops Q1 EPS by 12c, Beats on Revenue; offers FY27 Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
